Moncada B, Baranda M L, González-Amaro R, Urbina R, Loredo C E
Int J Lepr Other Mycobact Dis. 1985 Jun;53(2):201-5.
Thalidomide is the drug of choice in the erythema nodosum leprosum (ENL) type of lepra reaction. Lately it has been used successfully in other diseases, such as discoid lupus erythematosus, actinic prurigo, Behcet's disease, etc. However, its mechanism of action remains unknown. In patients for whom thalidomide provided relief in their disorder, the proportions of T lymphocytes and their subsets in peripheral blood were assessed by means of monoclonal antibodies. Three lepromatous leprosy patients with ENL had their T helper populations significantly increased after thalidomide therapy. A 14-year-old girl with Behcet's syndrome showed a consistent decrease in Ia+ cells throughout her three-month course of thalidomide therapy. The same findings were observed in two patients with the actinic prurigo type of polymorphous light eruption. From these results, we conclude that thalidomide may act as an immunomodulating agent on T cell subsets.
沙利度胺是麻风反应中结节性红斑型（ENL）的首选药物。最近，它已成功用于其他疾病，如盘状红斑狼疮、光化性瘙痒症、白塞病等。然而，其作用机制尚不清楚。对于使用沙利度胺后病情得到缓解的患者，通过单克隆抗体评估外周血中T淋巴细胞及其亚群的比例。三名结节性红斑型瘤型麻风患者在接受沙利度胺治疗后，其辅助性T细胞群体显著增加。一名14岁的白塞综合征女孩在整个三个月的沙利度胺治疗过程中，Ia +细胞持续减少。在两名光化性瘙痒型多形性日光疹患者中也观察到了相同的结果。从这些结果中，我们得出结论，沙利度胺可能作为一种免疫调节剂作用于T细胞亚群。
